Download PDF
Semin Neurol 2016; 36(02): 103-114
DOI: 10.1055/s-0036-1579693
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update

Alberto Ascherio
1   Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
2   Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
,
Kassandra L. Munger
1   Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
26 April 2016 (online)

    Permissions and Reprints

Abstract

Although genetic susceptibility explains the clustering of multiple sclerosis (MS) within families and the sharp decline in risk with increasing genetic distance, it cannot fully explain the geographical variations in MS frequency and the changes in risk that occur with migration, which support the action of strong environmental factors. Among these, vitamin D status, obesity in early life, infection with the Epstein-Barr virus, and cigarette smoking are the most consistent environmental predictors of MS risk. The authors review the epidemiological data, critically discuss the evidence for causality of these and other associations, and briefly review the possibility of interventions to reduce MS risk.

Keywords

multiple sclerosis - epidemiology - vitamin D - infection - environment
 

  • References

  • 1 Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17 (2) 210-218
    CrossrefPubMedGoogle Scholar
  • 2 Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol Scand Suppl 1995; 161 (Suppl): 23-33
    PubMedGoogle Scholar
  • 3 Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 2007; 78 (7) 707-709
    PubMedGoogle Scholar
  • 4 Koch-Henriksen N, Sorensen PS. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. J Neurol Sci 2011; 311 (1–2) 58-63
    CrossrefPubMedGoogle Scholar
  • 5 Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53 (8) 1711-1718
    CrossrefPubMedGoogle Scholar
  • 6 Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004; 55 (1) 65-71
    CrossrefPubMedGoogle Scholar
  • 7 Orton SM, Herrera BM, Yee IM , et al; Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5 (11) 932-936
    CrossrefPubMedGoogle Scholar
  • 8 Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9 (5) 520-532
    CrossrefPubMedGoogle Scholar
  • 9 Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand 1988; 78 (5) 369-380
    PubMedGoogle Scholar
  • 10 Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 1999; 5 (4) 293-296
    CrossrefPubMedGoogle Scholar
  • 11 Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61 (10) 1373-1377
    CrossrefPubMedGoogle Scholar
  • 12 Wallin MT, Culpepper WJ, Coffman P , et al; Veterans Affairs Multiple Sclerosis Centres of Excellence Epidemiology Group. The Gulf war era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012; 135 (Pt 6) 1778-1785
    CrossrefPubMedGoogle Scholar
  • 13 Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6) 548-552
    CrossrefPubMedGoogle Scholar
  • 14 Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008; 88 (6) 1519-1527
    CrossrefPubMedGoogle Scholar
  • 15 Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13 (7) 700-709
    CrossrefPubMedGoogle Scholar
  • 16 Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978; 28 (11) 1089-1093
    CrossrefPubMedGoogle Scholar
  • 17 Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 1966; 15 (3) 234-237
    CrossrefPubMedGoogle Scholar
  • 18 Dean G, Kurtzke JF. On the risk of multiple sclerosis according to age at immigration to South Africa. BMJ 1971; 3 (5777) 725-729
    CrossrefPubMedGoogle Scholar
  • 19 Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000; 123 (Pt 5) 968-974
    CrossrefPubMedGoogle Scholar
  • 20 Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47 (4–5) 425-448
    CrossrefPubMedGoogle Scholar
  • 21 Kurtzke JF, Beebe GW, Norman Jr JE. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 1985; 35 (5) 672-678
    CrossrefPubMedGoogle Scholar
  • 22 Compston A, Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep 2002; 2 (3) 259-266
    CrossrefPubMedGoogle Scholar
  • 23 Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80 (6, Suppl) 1678S-1688S
    CrossrefPubMedGoogle Scholar
  • 24 Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl 1960; 35 (147, Suppl) 132-147
    CrossrefPubMedGoogle Scholar
  • 25 Sutherland JM, Tyrer JH, Eadie MJ. The prevalence of multiple sclerosis in Australia. Brain 1962; 85: 149-164
    CrossrefPubMedGoogle Scholar
  • 26 Leibowitz U, Sharon D, Alter M. Geographical considerations in multiple sclerosis. Brain 1967; 90 (4) 871-886
    CrossrefPubMedGoogle Scholar
  • 27 Kurtzke JF. On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand 1967; 43 (3) 257-282
    CrossrefPubMedGoogle Scholar
  • 28 Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (A viewpoint) Part 1: sunlight, dietary factors and epidemiology. Int J Environ Stud 1974; 6: 19-27
    CrossrefPubMedGoogle Scholar
  • 29 Swank RL, Lerstad O, Strøm A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952; 246 (19) 722-728
    PubMedGoogle Scholar
  • 30 Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand 1970; 46 (4) 455-483
    CrossrefPubMedGoogle Scholar
  • 31 Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296 (23) 2832-2838
    CrossrefPubMedGoogle Scholar
  • 32 Munger KL, Levin LI, Massa J, Horst R, Orban T, Ascherio A. Preclinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am J Epidemiol 2013; 177 (5) 411-419
    CrossrefPubMedGoogle Scholar
  • 33 Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012; 79 (21) 2140-2145
    CrossrefPubMedGoogle Scholar
  • 34 Munger KL, Zhang SM, O'Reilly E , et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62 (1) 60-65
    CrossrefPubMedGoogle Scholar
  • 35 Willett WC, Sampson L, Browne ML , et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol 1988; 127 (1) 188-199
    CrossrefPubMedGoogle Scholar
  • 36 Salvini S, Hunter DJ, Sampson L , et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989; 18 (4) 858-867
    CrossrefPubMedGoogle Scholar
  • 37 Willett WC. Nutritional Epidemiology. 3rd ed. New York: Oxford University Press; 2012: 552
    CrossrefGoogle Scholar
  • 38 Giovannucci E, Stampfer MJ, Colditz GA , et al. A comparison of prospective and retrospective assessments of diet in the study of breast cancer. Am J Epidemiol 1993; 137 (5) 502-511
    CrossrefPubMedGoogle Scholar
  • 39 Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007; 254 (4) 471-477
    CrossrefPubMedGoogle Scholar
  • 40 Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult Scler 2014; 20 (6) 726-732
    CrossrefPubMedGoogle Scholar
  • 41 Cortese M, Riise T, Bjørnevik K , et al. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Mult Scler 2015; 21 (14) 1856-1864
    CrossrefPubMedGoogle Scholar
  • 42 Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008; 28 (1) 17-28
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Antonovsky A, Leibowitz U, Smith HA , et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. . Arch Neurol 1965; 13: 183-193
    CrossrefPubMedGoogle Scholar
  • 44 Cendrowski W, Wender M, Dominik W, Flejsierowicz Z, Owsianowski M, Popiel M. Epidemiological study of multiple sclerosis in western Poland. Eur Neurol 1969; 2 (2) 90-108
    CrossrefPubMedGoogle Scholar
  • 45 van der Mei IAF, Ponsonby AL, Dwyer T , et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327 (7410) 316-321
    CrossrefPubMedGoogle Scholar
  • 46 Lucas RM, Ponsonby AL, Dear K , et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011; 76 (6) 540-548
    CrossrefPubMedGoogle Scholar
  • 47 Bäärnhielm M, Hedström AK, Kockum I , et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol 2012; 19 (7) 955-962
    CrossrefPubMedGoogle Scholar
  • 48 Bjørnevik K, Riise T, Casetta I , et al. Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Mult Scler 2014; 20 (8) 1042-1049
    CrossrefPubMedGoogle Scholar
  • 49 Ponsonby AL, Lucas RM, van der Mei IA. UVR, vitamin D and three autoimmune diseases—multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 2005; 81 (6) 1267-1275
    CrossrefPubMedGoogle Scholar
  • 50 Mirzaei F, Michels KB, Munger K , et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 2011; 70 (1) 30-40
    CrossrefPubMedGoogle Scholar
  • 51 Ueda P, Rafatnia F, Bäärnhielm M , et al. Neonatal vitamin D status and risk of multiple sclerosis. Ann Neurol 2014; 76 (3) 338-346
    CrossrefPubMedGoogle Scholar
  • 52 Ascherio A, Munger KL. Not too late to take vitamin D supplements. Ann Neurol 2014; 76 (3) 321-322
    CrossrefPubMedGoogle Scholar
  • 53 Mokry LE, Ross S, Ahmad OS , et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med 2015; 12 (8) e1001866
    CrossrefPubMedGoogle Scholar
  • 54 Wang TJ, Zhang F, Richards JB , et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376 (9736) 180-188
    CrossrefPubMedGoogle Scholar
  • 55 Lucas RM, Ponsonby AL. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation?. Prog Biophys Mol Biol 2006; 92 (1) 140-149
    CrossrefPubMedGoogle Scholar
  • 56 van der Mei IA, Ponsonby AL, Dwyer T , et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254 (5) 581-590
    CrossrefPubMedGoogle Scholar
  • 57 Simpson Jr S, Taylor B, Blizzard L , et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68 (2) 193-203
    PubMedGoogle Scholar
  • 58 Runia TF, Hop WCJ, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012; 79 (3) 261-266
    CrossrefPubMedGoogle Scholar
  • 59 Mowry EM, Krupp LB, Milazzo M , et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010; 67 (5) 618-624
    PubMedGoogle Scholar
  • 60 Ascherio A, Munger KL, White R , et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71 (3) 306-314
    CrossrefPubMedGoogle Scholar
  • 61 Martinelli V, Dalla Costa G, Colombo B , et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014; 20 (2) 147-155
    CrossrefPubMedGoogle Scholar
  • 62 Kuhle J, Disanto G, Dobson R , et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015; 21 (8) 1013-1024
    CrossrefPubMedGoogle Scholar
  • 63 Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18 (8) 1144-1151
    CrossrefPubMedGoogle Scholar
  • 64 Stein MS, Liu Y, Gray OM , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77 (17) 1611-1618
    CrossrefPubMedGoogle Scholar
  • 65 Soilu-Hänninen M, Aivo J, Lindström BM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83 (5) 565-571
    CrossrefPubMedGoogle Scholar
  • 66 Smolders J, Hupperts R, Barkhof F , et al; SOLAR study group. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311 (1–2) 44-49
    CrossrefPubMedGoogle Scholar
  • 67 Dörr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012; 13 (1) 15
    CrossrefPubMedGoogle Scholar
  • 68 Bhargava P, Cassard S, Steele SU , et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39 (2) 288-293
    CrossrefPubMedGoogle Scholar
  • 69 Hayes CE, Hubler SL, Moore JR, Barta LE, Praska CE, Nashold FE. Vitamin D actions on CD4(+) T cells in autoimmune disease. Front Immunol 2015; 6: 100
    PubMedGoogle Scholar
  • 70 Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015; 7 (4) 3011-3021
    CrossrefPubMedGoogle Scholar
  • 71 Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135 (2) 317-322
    PubMedGoogle Scholar
  • 72 Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16 (7) 713-716
    CrossrefPubMedGoogle Scholar
  • 73 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69 (5) 842-856
    CrossrefPubMedGoogle Scholar
  • 74 Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77 (1) 204-210
    PubMedGoogle Scholar
  • 75 Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30 (5) 771-777
    CrossrefPubMedGoogle Scholar
  • 76 Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85 (3) 860-868
    PubMedGoogle Scholar
  • 77 Cooper JD, Smyth DJ, Walker NM , et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011; 60 (5) 1624-1631
    CrossrefPubMedGoogle Scholar
  • 78 Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev 2015; 16 (4) 341-349
    CrossrefPubMedGoogle Scholar
  • 79 Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009; 73 (19) 1543-1550
    CrossrefPubMedGoogle Scholar
  • 80 Munger KL, Bentzen J, Laursen B , et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 2013; 19 (10) 1323-1329
    CrossrefPubMedGoogle Scholar
  • 81 Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18 (9) 1334-1336
    CrossrefPubMedGoogle Scholar
  • 82 Wesnes K, Riise T, Casetta I , et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. Mult Scler 2015; 21 (4) 388-395
    CrossrefPubMedGoogle Scholar
  • 83 Gianfrancesco MA, Acuna B, Shen L , et al. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes Res Clin Pract 2014; 8 (5) e435-e447
    CrossrefPubMedGoogle Scholar
  • 84 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311 (8) 806-814
    CrossrefPubMedGoogle Scholar
  • 85 Sewell DL, Reinke EK, Hogan LH, Sandor M, Fabry Z. Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections. Immunol Lett 2002; 82 (1–2) 101-110
    CrossrefPubMedGoogle Scholar
  • 86 Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347 (12) 911-920
    CrossrefPubMedGoogle Scholar
  • 87 Niederman JC, Evans AS. Epstein-Barr virus. In: Evans AS, Kaslow RA, , eds. Viral Infections of Humans: Epidemiology and Control. 4th ed. New York: Plenum; 1997: 253-283
    CrossrefGoogle Scholar
  • 88 Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981; 2 (8258) 1290
    PubMedGoogle Scholar
  • 89 Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11 (2) 220-224
    CrossrefPubMedGoogle Scholar
  • 90 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61 (4) 288-299
    CrossrefPubMedGoogle Scholar
  • 91 Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004; 291 (15) 1875-1879
    CrossrefPubMedGoogle Scholar
  • 92 Pohl D, Krone B, Rostasy K , et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67 (11) 2063-2065
    CrossrefPubMedGoogle Scholar
  • 93 Banwell B, Krupp L, Kennedy J , et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6 (9) 773-781
    CrossrefPubMedGoogle Scholar
  • 94 Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59 (3) 499-503
    CrossrefPubMedGoogle Scholar
  • 95 Nielsen TR, Rostgaard K, Nielsen NM , et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64 (1) 72-75
    CrossrefPubMedGoogle Scholar
  • 96 Ascherio A, Munger KL, Lennette ET , et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286 (24) 3083-3088
    CrossrefPubMedGoogle Scholar
  • 97 Levin LI, Munger KL, Rubertone MV , et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293 (20) 2496-2500
    CrossrefPubMedGoogle Scholar
  • 98 DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63 (6) 839-844
    CrossrefPubMedGoogle Scholar
  • 99 Sundström P, Juto P, Wadell G , et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62 (12) 2277-2282
    CrossrefPubMedGoogle Scholar
  • 100 Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011; 17 (10) 1185-1193
    CrossrefPubMedGoogle Scholar
  • 101 Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67 (6) 824-830
    PubMedGoogle Scholar
  • 102 Ascherio A, Munger KL, Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8 (11) 602-612
    CrossrefPubMedGoogle Scholar
  • 103 James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18 (5) 462-467
    CrossrefPubMedGoogle Scholar
  • 104 Lang HL, Jacobsen H, Ikemizu S , et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3 (10) 940-943
    CrossrefPubMedGoogle Scholar
  • 105 Höllsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132 (1) 137-143
    CrossrefPubMedGoogle Scholar
  • 106 Holmøy T, Vartdal F. Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol 2004; 10 (1) 52-56
    CrossrefPubMedGoogle Scholar
  • 107 Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 2000; 173 (1) 32-39
    CrossrefPubMedGoogle Scholar
  • 108 Lennette ET, Rymo L, Yadav M , et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993; 29A (11) 1584-1589
    PubMedGoogle Scholar
  • 109 Kusunoki Y, Huang H, Fukuda Y , et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol 1993; 37 (6) 461-469
    CrossrefPubMedGoogle Scholar
  • 110 Lünemann JD, Edwards N, Muraro PA , et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006; 129 (Pt 6) 1493-1506
    CrossrefPubMedGoogle Scholar
  • 111 Cepok S, Zhou D, Srivastava R , et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115 (5) 1352-1360
    CrossrefPubMedGoogle Scholar
  • 112 Lossius A, Johansen JN, Vartdal F , et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol 2014; 44 (11) 3439-3452
    CrossrefPubMedGoogle Scholar
  • 113 van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler 2015;
    PubMedGoogle Scholar
  • 114 Mechelli R, Manzari C, Policano C , et al. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology 2015; 84 (13) 1362-1368
    CrossrefPubMedGoogle Scholar
  • 115 Hilton DA, Love S, Fletcher A, Pringle JH. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry 1994; 57 (8) 975-976
    CrossrefPubMedGoogle Scholar
  • 116 Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2 (4) 249-258
    CrossrefPubMedGoogle Scholar
  • 117 Opsahl ML, Kennedy PG. An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. J Neurol 2007; 254 (4) 425-430
    CrossrefPubMedGoogle Scholar
  • 118 Serafini B, Rosicarelli B, Franciotta D , et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204 (12) 2899-2912
    CrossrefPubMedGoogle Scholar
  • 119 Magliozzi R, Serafini B, Rosicarelli B , et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol 2013; 72 (1) 29-41
    CrossrefPubMedGoogle Scholar
  • 120 Willis SN, Stadelmann C, Rodig SJ , et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132 (Pt 12) 3318-3328
    CrossrefPubMedGoogle Scholar
  • 121 Sargsyan SA, Shearer AJ, Ritchie AM , et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74 (14) 1127-1135
    CrossrefPubMedGoogle Scholar
  • 122 Peferoen LA, Lamers F, Lodder LN , et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010; 133 (Pt 5) e137
    CrossrefPubMedGoogle Scholar
  • 123 Torkildsen Ø, Stansberg C, Angelskår SM , et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol 2010; 20 (4) 720-729
    PubMedGoogle Scholar
  • 124 Ascherio A, Bar-Or A. EBV and brain matter(s)?. Neurology 2010; 74 (14) 1092-1095
    CrossrefPubMedGoogle Scholar
  • 125 Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM ; NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 2011; 134 (Pt 9) 2772-2786
    CrossrefPubMedGoogle Scholar
  • 126 Lycke J, Svennerholm B, Hjelmquist E , et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996; 243 (3) 214-224
    CrossrefPubMedGoogle Scholar
  • 127 Friedman JE, Zabriskie JB, Plank C , et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005; 11 (3) 286-295
    CrossrefPubMedGoogle Scholar
  • 128 Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 1993; 47 (2) 161-168
    CrossrefPubMedGoogle Scholar
  • 129 Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998; 105 (12) 1296-1299
    CrossrefPubMedGoogle Scholar
  • 130 Hernán MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001; 154 (1) 69-74
    CrossrefPubMedGoogle Scholar
  • 131 Hernán MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128 (Pt 6) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 132 Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 2001; 92 (4) 281-285
    PubMedGoogle Scholar
  • 133 Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand 2002; 105 (2) 77-82
    CrossrefPubMedGoogle Scholar
  • 134 Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008; 14 (8) 1031-1035
    CrossrefPubMedGoogle Scholar
  • 135 Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73 (9) 696-701
    CrossrefPubMedGoogle Scholar
  • 136 Ramagopalan SV, Lee JD, Yee IM , et al. Association of smoking with risk of multiple sclerosis: a population-based study. J Neurol 2013; 260 (7) 1778-1781
    CrossrefPubMedGoogle Scholar
  • 137 Briggs FB, Acuna B, Shen L , et al. Smoking and risk of multiple sclerosis: evidence of modification by NAT1 variants. Epidemiology 2014; 25 (4) 605-614
    CrossrefPubMedGoogle Scholar
  • 138 Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003; 61 (8) 1122-1124
    CrossrefPubMedGoogle Scholar
  • 139 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61 (6) 504-513
    CrossrefPubMedGoogle Scholar
  • 140 Sundström P, Nyström L, Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol 2008; 15 (6) 579-583
    CrossrefPubMedGoogle Scholar
  • 141 Hedström AK, Sundqvist E, Bäärnhielm M , et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011; 134 (Pt 3) 653-664
    CrossrefPubMedGoogle Scholar
  • 142 Simon KC, van der Mei IA, Munger KL , et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74 (17) 1365-1371
    CrossrefPubMedGoogle Scholar
  • 143 Palacios N, Alonso A, Brønnum-Hansen H, Ascherio A. Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann Epidemiol 2011; 21 (7) 536-542
    CrossrefPubMedGoogle Scholar
  • 144 Courville CB, Maschmeyer JE, Delay CP. Effects of smoking on the acute exacerbations of multiple sclerosis. Bull Los Angel Neuro Soc 1964; 29: 1-6
    PubMedGoogle Scholar
  • 145 Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol 1992; 49 (12) 1243-1247
    CrossrefPubMedGoogle Scholar
  • 146 Healy BC, Ali EN, Guttmann CR , et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66 (7) 858-864
    CrossrefPubMedGoogle Scholar
  • 147 Di Pauli F, Reindl M, Ehling R , et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008; 14 (8) 1026-1030
    CrossrefPubMedGoogle Scholar
  • 148 Munger KL, Fitzgerald KC, Freedman MS , et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 2015; 85 (19) 1694-1701
    CrossrefPubMedGoogle Scholar
  • 149 Hawkins BT, Brown RC, Davis TP. Smoking and ischemic stroke: a role for nicotine?. Trends Pharmacol Sci 2002; 23 (2) 78-82
    CrossrefPubMedGoogle Scholar
  • 150 Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006; 15 (11) 737-745
    CrossrefPubMedGoogle Scholar
  • 151 Hedström AK, Hillert J, Olsson T, Alfredsson L. Nicotine might have a protective effect in the etiology of multiple sclerosis. Mult Scler 2013; 19 (8) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 152 Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS ONE 2014; 9 (9) e107979
    CrossrefPubMedGoogle Scholar
  • 153 Gao Z, Nissen JC, Legakis L, Tsirka SE. Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis. Neuroscience 2015; 297: 11-21
    CrossrefPubMedGoogle Scholar
  • 154 Odoardi F, Sie C, Streyl K , et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012; 488 (7413) 675-679
    CrossrefPubMedGoogle Scholar
  • 155 Jamal A, Agaku IT, O'Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults—United States, 2005-2013. MMWR Morb Mortal Wkly Rep 2014; 63 (47) 1108-1112
    Google Scholar
  • 156 Rothman K, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998
    Google Scholar
  • 157 Farez MF, Fiol MP, Gaitán MI, Quintana FJ, Correale J. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015; 86 (1) 26-31
    CrossrefPubMedGoogle Scholar
  • 158 Massa J, O'Reilly EJ, Munger KL, Ascherio A. Caffeine and alcohol intakes have no association with risk of multiple sclerosis. Mult Scler 2013; 19 (1) 53-58
    CrossrefPubMedGoogle Scholar
  • 159 D'hooghe MB, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012; 19 (4) 616-624
    CrossrefPubMedGoogle Scholar
  • 160 Hedström AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol 2014; 71 (3) 300-305
    CrossrefPubMedGoogle Scholar
  • 161 Pekmezovic T, Drulovic J, Milenkovic M , et al. Lifestyle factors and multiple sclerosis: a case-control study in Belgrade. Neuroepidemiology 2006; 27 (4) 212-216
    CrossrefPubMedGoogle Scholar